Tyra Biosciences Says Phase 2 SURF302 Study Of Oral Dabogratinib In Low-Grade IR NMIBC Showed 79% ORR, 64% Best Overall Complete Response Rate At 60 mg QD; Says 100% ORR In Single Marker Lesion Patients, Identifies 60 mg As Phase 3 Adjuvant Dose
Share
Why It Matters
Tyra Biosciences tested a new cancer medicine and found it worked really well in their study—most patients got better. When a company's medicine shows strong results like this, it's a sign the company might be on track, so people watch to see what happens next.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.